**BCR Signaling Contributes to Autophagy Regulation in Chronic Lymphocytic Leukemia**

**Running Title:** BCR signaling and autophagy.

Lindsay D. Smith1\*, Annabel R. Minton1,Matthew D. Blunt1, Laura I. Karydis1, David A. Dutton1, Karly-Rai Rogers-Broadway1, Rachel Dobson1, Rena Liu1, Faith Norster2, Elizabeth Hogg1, Margaret Ashton-Key3, Jonathan C. Strefford1, Li Jia2, Dimitar G. Efremov4, G. Vignir Helgason5, Peter W. M. Johnson1, Freda K. Stevenson1, Francesco Forconi1, Mark S. Cragg1, David A. Tumbarello6, Graham Packham1, Andrew J. Steele1\*.

1Cancer Sciences, University of Southampton, Somers Cancer Sciences Building, Southampton General Hospital, Southampton, SO16 6YD, United Kingdom. 2Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ, United Kingdom. 3Department of Cellular Pathology, Southampton University Hospital Trust, SO17 1BJ, United Kingdom. 4Molecular Hematology Unit, International Centre for Genetic Engineering & Biotechnology, Padriciano 99, 34149 Trieste, Italy. 5Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, G12 0ZD, United Kingdom. 6Institute for Life Sciences, University of Southampton, University Road, Highfield Campus, Southampton, SO17 1BJ, United Kingdom.

**\*Corresponding Author:** Andrew J. Steele, Email: [a.steele@soton.ac.uk](mailto:a.steele@soton.ac.uk); Lindsay D. Smith, Email: [L.D.Smith@soton.ac.uk](mailto:L.D.Smith@soton.ac.uk)

Somers Cancer Research Building (MP 824), Southampton General Hospital, Tremona Road, Southampton, SO16 6YD. Tel: 023 8120 5170. Fax: 023 8120 5152.

**Competing Interests:** The authors declare no competing financial interests.

**Words:** 1492

**Number of Figures:** 2

Chronic lymphocytic leukemia (CLL) is characterised by the accumulation of tumor B-cells within the blood and tissues.1 Whilst patients with unmutated (U-CLL) or mutated (M-CLL) *IGHV*-genes typically have a progressive or indolent disease respectively. B-cell receptor (BCR) signaling adds a further complexity and is pivotal to CLL pathogenesis, promoting tumour survival, proliferation and consequently tumour progression.2 Indeed inhibition of this pathway has revolutionised clinical responses in patients.3

Macroautophagy (herein Autophagy) maintains cellular homeostasis through bulk protein degradation. During the autophagy process LC3 (microtubule associated protein 1 light chain 3) and GABARAP (GABA type A receptor proteins) family proteins, ATG3 and ATG7 are essential for autophagosome formation, autophagosome-lysosome fusion, and cargo degradation (**Supplementary Figure S1**).4 In CLL, high basal expression of autophagy genes, BECN1, PIK3C3 and PIK3R4, have been associated with a shorter time-to-first treatment (TTFT) and worse overall survival in patients.5 Furthermore, BECN1 and ATG5 RNA expression have been shown to correlate with poorer clinical outcome,6 and autophagy was shown to reduce therapy-induced apoptosis.7 However, how BCR activation regulates autophagy in CLL has not previously been evaluated.

Evaluation of basal autophagy-protein levels demonstrated significantly greater LC3B-II, GABARAPL2, ATG3 and ATG7 in CLL cases (**Supplementary Table S1;** for antibody information see **Supplementary Table S2)** compared to healthy donor B-cells (HDB) (**Figure 1A; Supplementary Figure S2A**). The basal levels of LC3B-II, but not GABARAPL2, ATG3 or ATG7, were significantly greater still in U-CLL compared to M-CLL (**Figure 1B; Supplementary Figure S2B**). Additionally, LC3B-II and ATG3 levels, but not GABARAPL2 or ATG7, associated with BCR signaling capacity (**Figure 1C; Supplementary Figure S2C**). With significantly greater levels of LC3B-II and ATG3 observed within U-CLL compared to MCLL-LS due to the contrasting extremes of anti-IgM-mediated signaling between these two subgroups. M-CLL-S samples that retained anti-IgM signaling capacity expressed LC3B-II at an intermediate level between U-CLL and M-CLL-LS cases (**Figure 1C**); suggesting LC3B-II levels were influenced by both inherent BCR signaling and the cells origin. Indeed, greater LC3B-II levels were associated with a significantly shorter TTFT from first lymphocytosis (**Supplementary** **Figure S3A)** irrespective of *IGHV* mutational status, since both cohorts expressed a mixture of U-CLL and M-CLL cases**.** Intriguingly, although numbers were small, LC3B-II expression also appeared to identify M-CLL patients, but not U-CLL patients, that required earlier treatment (**Supplementary Figure S3B)**.However, further work in a larger trial using a fully quantitative technique is required to identify the potential of LC3B-II as a biomarker.

To determine whether autophagy occurred *in vivo*, we performed immunohistochemistry on lymph node tissue from CLL patients and control tissue from healthy, reactive nodes. LC3B expression was detected most strongly within proliferation centres from sequential tissue sections labelled with Ki67 (**Supplementary** **Figure S4A,B**), and in reactive node germinal centers (**Supplementary Figure S4D**). This shows that LC3B expression is associated with CLL cells and B-cells that had undergone antigen-engagement. These cells appeared to be B-cells given that the majority of cells were CD20+ in sequential tissue sections (**Supplementary Figure S4C,D**).

Consequently, we assessed whether BCR-engagement for 2, 4 or 24 hours with bead-bound anti-IgM or anti-IgD could modify expression of key autophagy proteins LC3B-II, GABARAPL2, ATG3 and ATG7 in CLL cells **(Figure 1D; Supplementary Figure S5A,B)**. Significant increases in the level of all proteins were observed 24 hours following treatment with anti-IgM. Whilst significant increases in GABARAPL2 and LC3B-II also occurred earlier between 2-4 hours, ATG3 and ATG7 only demonstrated trends for increased expression. Subsequent evaluation of LC3B-II expression in a larger cohort of patients treated with bead-bound anti-IgM for 24 hours demonstrated that the majority of CLL cases activated their autophagy pathway in response to BCR-engagement (**Supplementary Figure S5C**). Furthermore, U-CLL cases expressed greater levels of LC3B-II in response to anti-IgM compared to M-CLL cases (median fold-increase of 5.4 and 3.5 respectively; **Figure 1E**). Some overlap in the anti-IgM-mediated LC3B-II levels was identified between *IGHV* subsets that maybe a result of M-CLL cases with active BCR signaling. Compared to anti-IgM, anti-IgD induced signaling is short-lived in CLL cases.8 Therefore although significant increases in LC3B-II were observed following bead-bound anti-IgD treatment at all time-points, with trends for increased GABARAPL2, in most instances these increases were smaller than that observed with anti-IgM (**Supplementary Figure S5D**). Similarly, a small but significant increase in ATG7 levels were observed at 24 hours with bead-bound anti-IgD, with only a trend for increased ATG3 expression at 24 hours **(Supplementary Figure S5D**).

We subsequently characterised the signaling pathways involved in BCR-mediated autophagy (**Supplementary Figure S6**). Phospho-ERK and -AKT levels increased 15 minutes post-stimulation with bead-bound anti-IgM or anti-IgD, which is indicative of active BCR signaling. Interestingly, anti-IgM and anti-IgD increased phospho-p70 S6 kinase levels at 6 hours indicating active mTOR signalling, despite an induction of LC3B-II expression, suggesting activation of non-canonical autophagy.9 At 24 hours, anti-IgM and anti-IgD-dependent increases in LC3B-II, p62 and phospho-ATG13 suggested simultaneous activation of canonical and non-canonical autophagy.9, 10

Next, we assessed autophagosome formation using LC3B puncta formation by immunofluorescence.11 Basal autophagy was observed in cells treated with bead-bound control antibody (**Supplementary Figure S7A,B**), whilst treatment with bead-bound anti-IgM increased LC3B puncta to levels above that seen in the control (**Supplementary Figure S7A,B**).

To confirm that bead-bound anti-IgM-mediated autophagy was BCR-mediated and not a bead-dependent affect, CLL cells were treated with bead-bound or soluble anti-IgM in the presence or absence of the autophagosome inhibitor, hydroxychloroquine (HCQ). Both soluble and bead-bound anti-IgM significantly increased LC3B-II and GABARAPL2 levels compared to the control (**Supplementary Figure S8A,B**), confirming that the induction of autophagy proteins was mediated by BCR-engagement and was not a bead-dependent effect. Treatment with soluble anti-IgM resulted in smaller autophagy protein increases in the same CLL samples compared to bead-bound anti-IgM, likely due to the relatively higher BCR signal strength and duration with bead-bound verse soluble anti-IgM.12

To determine whether the anti-Ig-dependent regulation of autophagy was B-cell or tumor specific we treated HDB with bead-bound or soluble anti-IgM or anti-IgD for 24 hours. Bead-bound anti-IgM, and to a lesser extent anti-IgD, promoted significant increases in LC3B-II levels (**Supplementary Figure S9A,B**), suggesting that this phenomenon was B-cell and not tumor-specific. However, in contrast to CLL, these changes were not consistently replicated in the other autophagy markers examined.

To determine whether BCR-engagement blocked LC3B-II degradation or induced autophagosome formation, we assessed autophagic flux in response to bead-bound anti-IgM using immunoblotting in the presence or absence of HCQ as described in the autophagy guidelines.11 CLL cells treated with HCQ accumulated LC3B-II in a concentration-dependent manner, which was further augmented with bead-bound anti-IgM (**Figure 2A**). The LC3B-II increases were not a result of HCQ-mediated effects on BCR signaling **(Supplementary Figure S10)** and also occurred in a time-dependent manner at the RNA level (**Supplementary Figure S11A**). Comparatively, bead-bound anti-IgD stimulation produced similar but much smaller responses than anti-IgM (**Supplementary Figure S11B**). These data confirm that BCR-engagement does not block autosomal degradation, but induces the expression of autophagy-associated genes leading to increased autophagic flux.

Next, we utilised IL-4 and BCR kinase inhibitors to confirm the role of BCR signaling in the regulation of BCR-mediated autophagy in CLL. We previously demonstrated that IL-4 induced surface IgM (sIgM) expression and subsequent downstream signaling.13 IL-4 treatment significantly increased sIgM expression as previously demonstrated and augmented anti-IgM-dependent LC3B-II levels (**Figure 2B; Supplementary Figure S12A,B**). These affects appeared to be BCR-mediated since IL-4 had no substantive effect on LC3B-II levels alone, even in the presence of HCQ. Next, we inhibited BCR signaling with tamatinib (SYK) and Ibrutinib (BTK) and observed the effect on LC3B-II levels. Both inhibitors significantly reduced LC3B-II to basal levels (**Figure 2C; Supplementary Figure S12C**). These data confirm the role of BCR signaling in the regulation of autophagy in CLL.

Previous studies have shown a role for autophagy in resistance to venetoclax-mediated killing in follicular lymphoma.14 Therefore we hypothesised that autophagy inhibitors may synergise with established therapies to inhibit basal, BCR-induced, or therapy-induced autophagy in CLL. To address this we examined the effect on CLL cell viability of combining the autophagy inhibitor, VPS34-IN1, with venetoclax following bead-bound anti-IgM treatment. We observed significant synergy between VPS34-IN1 and venetoclax compared to single-agent treatment (**Figure 2D,E**). Importantly, VPS34-IN1 inhibited BCR-mediated LC3B-II increases but had no effect on BCR signaling (**Supplementary Figure S13A,B**), and both ABT-199 and VPS34-IN1-mediated cell death was largely caspase-dependent (**Figure 2D**). These data indicate a protective cellular effect of BCR-mediated autophagy in CLL and highlight the therapeutic potential of inhibiting autophagy pathways to promote greater CLL cell killing.

**Acknowledgements:** We thank Bloodwise (14040, 16003), CRUK (C2750/A23669), the patients for supplying tissue, the support from CRUK centre grant (C34999/A18087) and ECMC grant (C24563/A15581). We thank Dr Ian Tracy and Dr Kathy Potter, Mrs Isla Henderson, and Ms Carina Mundy for sample characterisation and storage. We thank Dr Sonya James and the University of Southampton Biomedical Imaging Unit. We thank Professor Sharon Tooze for reading the manuscript and providing scientific guidance. Finally, we acknowledge Professor Tessa Holyoake who was a collaborator on this study but who passed away before project completion.

Supplementary information is available at Leukemia www.nature.com/leu/

**References**

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. *N Engl J Med* 2005 Feb 24; **352**(8)**:** 804-815.

2. Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. *Blood* 2011 Oct 20; **118**(16)**:** 4313-4320.

3. Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. *Blood* 2012; **120**(6)**:** 1175-1184.

4. Yu L, Chen Y, Tooze SA. Autophagy pathway: Cellular and molecular mechanisms. *Autophagy* 2018; **14**(2)**:** 207-215.

5. Kristensen L, Kristensen T, Abildgaard N, Thomassen M, Frederiksen M, Mourits-Andersen T*, et al.* High expression of PI3K core complex genes is associated with poor prognosis in chronic lymphocytic leukemia. *Leuk Res* 2015 Jun; **39**(6)**:** 555-560.

6. Kong YL, Huang Y, Wu JZ, Cao X, Liang JH, Xia Y*, et al.* Expression of autophagy related genes in chronic lymphocytic leukemia is associated with disease course. *Leuk Res* 2018 Jan 3; **66:** 8-14.

7. Mahoney E, Lucas DM, Gupta SV, Wagner AJ, Herman SE, Smith LL*, et al.* ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. *Blood* 2012 Aug 9; **120**(6)**:** 1262-1273.

8. Ten Hacken E, Sivina M, Kim E, O'Brien S, Wierda WG, Ferrajoli A*, et al.* Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia. *J Immunol* 2016 Sep 15; **197**(6)**:** 2522-2531.

9. Martinez-Martin N, Maldonado P, Gasparrini F, Frederico B, Aggarwal S, Gaya M*, et al.* A switch from canonical to noncanonical autophagy shapes B cell responses. *Science* 2017 Feb 10; **355**(6325)**:** 641-647.

10. Hieke N, Loffler AS, Kaizuka T, Berleth N, Bohler P, Driessen S*, et al.* Expression of a ULK1/2 binding-deficient ATG13 variant can partially restore autophagic activity in ATG13-deficient cells. *Autophagy* 2015; **11**(9)**:** 1471-1483.

11. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A*, et al.* Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy* 2016; **12**(1)**:** 1-222.

12. Krysov S, Steele AJ, Coelho V, Linley A, Sanchez Hidalgo M, Carter M*, et al.* Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK. *Blood* 2014 Nov 13; **124**(20)**:** 3101-3109.

13. Aguilar-Hernandez MM, Blunt MD, Dobson R, Yeomans A, Thirdborough S, Larrayoz M*, et al.* IL-4 enhances expression and function of surface IgM in CLL cells. *Blood* 2016 Jun 16; **127**(24)**:** 3015-3025.

14. Bodo J, Zhao X, Durkin L, Souers AJ, Phillips DC, Smith MR*, et al.* Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells. *Oncotarget* 2016 Oct 25; **7**(43)**:** 70000-70010.

**Figure Legends**

**Figure 1. Characterization of autophagy-marker protein levels at baseline and following BCR-engagement.** (**A**) Protein was extracted from snap-frozen PBMCs isolated from CLL patients or HDB purified by negative selection. The level of LC3B-II (n=43), GABARAPL2 (n=19), ATG3 (n=42) and ATG7 (n=40) was quantified by immunoblotting and normalized protein levels relative to the Hsc70 loading control are shown. Mean values are indicated. A Mann-Whitney test was used for statistical analysis.(**B**) Basal LC3B-II protein levels in CLL samples (n=43) divided by *IGHV* mutational status into mutated (M-CLL) and unmutated (U-CLL) cases, and (**C**) BCR signaling capacity defined by U-CLL, M-CLL signallers (M-CLL-S) (>5% iCa2+ flux) and M-CLL low signallers (M-CLL-LS) (≤5% iCa2+ flux).Mean values are indicated. A Mann-Whitney test was used for statistical analysis.(**D**) CLL samples were treated with bead-bound isotype control antibody (IC), anti-IgM or anti-IgD for 2, 4 or 24 hours and the level of LC3B-II (n=21) assessed by immunoblotting. Blots were quantified and the mean fold-change (± S.E.M) in the level of LC3B-II with anti-IgM normalised to the IC at 2 hours is shown. A Wilcoxon matched-pairs signed rank test used for statistical analysis. (**E**) A larger cohort of patient samples (n=45) were treated with bead-bound anti-IgM for 24 hours and LC3B-II levels divided according to *IGHV* status into M-CLL and U-CLL as previously described. Mean values are indicated. A Mann Whitney test was used for statistical analysis.

**Figure 2. BCR-mediated autophagy is dependent on BCR signaling and provides a survival advantage to CLL cells.** (**A**)CLL samples (n=11) were treated with bead-bound isotype control antibody (IC) or anti-IgM with or without HCQ at indicated concentrations for 24 hours and LC3B-II levels evaluated by immunoblotting. A representative immunoblot is shown. Blots were quantified and the mean fold-change (± S.E.M) in LC3B-II level with each treatment versus IC without HCQ is shown in the accompanying graph. A t-test was used for statistical analysis. (**B**) CLL samples (n=6) were treated with or without IL-4 (10ng/ml), in the presence or absence of HCQ, for 24 hours prior to treatment with bead-bound IC or anti-IgM for 24 hours. LC3B-II levels were evaluated by immunoblotting and the mean fold-change (± S.E.M) in LC3B-II levels with each treatment versus IC without HCQ is shown. A Wilcoxon matched-pairs signed rank test was used for statistical analysis. (**C**) CLL samples (n=10) were treated with HCQ and a SYK (tamatinib; Tam) or BTK (ibrutinib; Ibr) inhibitor (both 5μM) for 1 hour prior to stimulation with bead-bound IC or anti-IgM for 24 hours and the LC3B-II level evaluated by immunoblotting. Hsc70 was used as a loading control. A representative immunoblot is shown. Blots were quantified and the mean fold change (± S.E.M) in LC3B-II level with each treatment versus IC DMSO is shown in the accompanying graph. A Wilcoxon matched-pairs signed rank test was used for statistical analysis. (**D**) CLL samples were treated for 6 hours with bead-bound IC or anti-IgM prior to treatment with autophagy inhibitor, VPS34-IN1 (3μM), either alone or in combination with venetoclax (5nM n=6, or 10nM n=8 where shown) for 24 hours. All conditions were carried out with or without Q-VD-Ph (10μM) to identify caspase-dependent drug-mediated cell killing. Cell viability was assessed by the CellTiter-Glo Cell Viability Assay. The mean (+S.E.M) percentage of viable cells relative to IC is shown. A Wilcoxon matched-pairs signed rank test was used for statistical analysis. (**E**) Synergy between VPS34-IN1 (3μM) and venetoclax (5nm, left and 10nM, right) was evaluated as detailed in the Supplementary materials and methods. XY line, observed survival = expected survival. Points below the line, synergistic interactions; points above the line, additive interactions.